Experience

Hello Group Acquires Happn

September 24, 2025

Cooley advised Hello Group, a leading player in Asia’s online social networking space, on its acquisition of Happn, a French location-based social search mobile and web application that enables users to connect with others based on their proximity and interests.

Read more

Related contacts

Yilin Xu
Partner, Beijing
Will Cai
Partner, Hong Kong
Ruomu Li
Partner, Shanghai
Michael Shen
Special Counsel, Shanghai
Lunga Su
Associate, Shanghai
Bartholomäus Regenhardt
Associate, Brussels
Patrick Van Eecke
Partner, Brussels
Charles Haley
Partner, Palo Alto
Xander Lee
Partner, Santa Monica
Hardy Zhou
Associate, New York
Athina Gaki
Associate, Brussels
Julie Paulino Montejo
Associate, New York
Len Jacoby
Partner, New York
Christopher Kimball
Partner, Washington, DC
John Paul Oleksiuk
Partner, New York
Sharon Connaughton
Special Counsel, Washington, DC
Dillon Martinson
Special Counsel, Washington, DC
Yi Jia Ng
Special Counsel, Singapore
Anna Caro
Associate, London
Michael Pelle
Associate, New York
Harvey Yao
Associate, Hong Kong
Veronica Cortes
Paralegal Specialist, New York

Related Practices & Industries

Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by Syndicate of Premier Healthcare Investors

August 9, 2023

Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, on its private placement financing of up to $150 million.

Read more

Related contacts

Will Cai
Partner, Hong Kong
Jie Zhang
Counsel, Hong Kong
Francis Wheeler
Senior Counsel, Colorado
Hilda Li
Associate, Hong Kong
Harvey Yao
Associate, Hong Kong
Zhengyang Li
International Legal Project Manager, Hong Kong

Related Practices & Industries

Summit Healthcare Closes Business Combination With YS Biopharma

March 20, 2023

Cooley advised Summit Healthcare Acquisition Corp. (Summit Healthcare), a publicly traded special purpose acquisition company, on its business combination with YishengBio Co., Ltd. (YS Biopharma), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of innovative vaccines and therapeutic biologics.

Read more

Related contacts

Will Cai
Partner, Hong Kong
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Tim Pitrelli
Partner, Singapore
Steven Holm
Counsel, Singapore
Hilda Li
Associate, Hong Kong
Harvey Yao
Associate, Hong Kong
Aaron Pomeroy
Partner, Colorado
Rick Jantz
Associate, Santa Monica
Calvin Lee
Associate, New York

Admissions and credentials

New York

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.